Literature DB >> 35298669

Role of the innate and adaptive immune responses in the pathogenesis of systemic lupus erythematosus.

Nasim Bolouri1,2, Maryam Akhtari2,3, Elham Farhadi4,5, Reza Mansouri1, Seyedeh Tahereh Faezi2, Ahmadreza Jamshidi2, Mahdi Mahmoudi2,3.   

Abstract

OBJECTIVE: Systemic lupus erythematosus (SLE), the most common form of lupus, is a multisystemic rheumatic disease with different clinical features that generally affect women of childbearing age. The common symptoms of SLE are very similar to other autoimmune and non-autoimmune disorders, thereby it is known as a thousand faces disease. In this article, we are going to discuss some of the most updated information about immune system-related factors, cells, and cytokines involved in SLE pathogenesis.
METHODS: Different electronic databases, especially PubMed/MEDLINE, Scopus, and Google Scholar, were searched to review and analyze relevant literature on the role of innate and adaptive immune cells and cytokines in the pathogenesis of SLE. A search for relevant literature was accomplished using various keywords including systemic lupus erythematosus, apoptosis, autoantibodies, immunopathogenesis of SLE, adaptive and innate immune cells, inflammatory cytokines, hormones, etc. RESULTS AND
CONCLUSION: The most important characteristic of SLE is the production of antibodies against different nuclear autoantigens like double-strand DNA and RNA. The depositions of the immune complexes (ICs) that are generated between autoantibodies and autoantigens, along with aberrant clearance of them, can lead to permanent inflammation and contribute to tissue or organ damage. Related mechanisms underlying the initiation and development of SLE have not been clarified yet. Although, defects in immune tolerance, enhanced antigenic load, hyperactivity of T cells, and inappropriate regulation of B cells contribute to the pathogenic autoantibodies generation. Besides, sex hormones that influence the immune system seem to act as triggers or protectors of SLE development.
© 2022. The Author(s), under exclusive licence to Springer Nature Switzerland AG.

Entities:  

Keywords:  Cytokines; Immune cells; Immunopathogenesis; Systemic lupus erythematosus

Mesh:

Substances:

Year:  2022        PMID: 35298669     DOI: 10.1007/s00011-022-01554-6

Source DB:  PubMed          Journal:  Inflamm Res        ISSN: 1023-3830            Impact factor:   4.575


  128 in total

1.  Plasmacytoid dendritic cells (natural interferon- alpha/beta-producing cells) accumulate in cutaneous lupus erythematosus lesions.

Authors:  L Farkas; K Beiske; F Lund-Johansen; P Brandtzaeg; F L Jahnsen
Journal:  Am J Pathol       Date:  2001-07       Impact factor: 4.307

Review 2.  The complement system in systemic lupus erythematosus: an update.

Authors:  Jonatan Leffler; Anders A Bengtsson; Anna M Blom
Journal:  Ann Rheum Dis       Date:  2014-05-20       Impact factor: 19.103

3.  Impaired phagocytosis by peripheral blood granulocytes in systemic lupus erythematosus.

Authors:  L Brandt; H Hedberg
Journal:  Scand J Haematol       Date:  1969

Review 4.  New insights into the immunopathogenesis of systemic lupus erythematosus.

Authors:  George C Tsokos; Mindy S Lo; Patricia Costa Reis; Kathleen E Sullivan
Journal:  Nat Rev Rheumatol       Date:  2016-11-22       Impact factor: 20.543

5.  Lupus erythematosus associated with genetically determined deficiency of the second component of the complement.

Authors:  D M Lipsker; C Schreckenberg-Gilliot; B Uring-Lambert; A Meyer; D Hartmann; E M Grosshans; G Hauptmann
Journal:  Arch Dermatol       Date:  2000-12

Review 6.  The complement system as a potential therapeutic target in rheumatic disease.

Authors:  Leendert A Trouw; Matthew C Pickering; Anna M Blom
Journal:  Nat Rev Rheumatol       Date:  2017-08-10       Impact factor: 20.543

7.  Anti-DNA autoreactivity in C4-deficient mice.

Authors:  Elahna Paul; Olga O Pozdnyakova; Elizabeth Mitchell; Michael C Carroll
Journal:  Eur J Immunol       Date:  2002-09       Impact factor: 5.532

8.  Superoxide anion production by neutrophils is associated with prevalent clinical manifestations in systemic lupus erythematosus.

Authors:  Celene M O S Alves; Cleni M Marzocchi-Machado; Paulo Louzada-Junior; Ana Elisa C S Azzolini; Ana Cristina M Polizello; Ivan F de Carvalho; Yara M Lucisano-Valim
Journal:  Clin Rheumatol       Date:  2007-10-23       Impact factor: 2.980

Review 9.  The Involvement of MicroRNAs in Modulation of Innate and Adaptive Immunity in Systemic Lupus Erythematosus and Lupus Nephritis.

Authors:  Mohsen Honarpisheh; Paulina Köhler; Ekaterina von Rauchhaupt; Maciej Lech
Journal:  J Immunol Res       Date:  2018-05-08       Impact factor: 4.818

Review 10.  Innate Immune Cells' Contribution to Systemic Lupus Erythematosus.

Authors:  Andrés A Herrada; Noelia Escobedo; Mirentxu Iruretagoyena; Rodrigo A Valenzuela; Paula I Burgos; Loreto Cuitino; Carolina Llanos
Journal:  Front Immunol       Date:  2019-04-15       Impact factor: 7.561

View more
  4 in total

Review 1.  Artemisinin derivative SM934 in the treatment of autoimmune and inflammatory diseases: therapeutic effects and molecular mechanisms.

Authors:  Xiao Tong; Li Chen; Shi-Jun He; Jian-Ping Zuo
Journal:  Acta Pharmacol Sin       Date:  2022-09-01       Impact factor: 7.169

Review 2.  Immune Modulation Using Extracellular Vesicles Encapsulated with MicroRNAs as Novel Drug Delivery Systems.

Authors:  Yasunari Matsuzaka; Ryu Yashiro
Journal:  Int J Mol Sci       Date:  2022-05-18       Impact factor: 6.208

3.  Analysis of Peripheral Blood Basophils in Pediatric Systemic Lupus Erythematosus.

Authors:  Kuanysh Dossybayeva; Yergali Bexeitov; Zaure Mukusheva; Zhaina Almukhamedova; Maykesh Assylbekova; Diyora Abdukhakimova; Marzhan Rakhimzhanova; Dimitri Poddighe
Journal:  Diagnostics (Basel)       Date:  2022-07-12

Review 4.  Jak Inhibitors for Treatment of Autoimmune Diseases: Lessons from Systemic Sclerosis and Systemic Lupus Erythematosus.

Authors:  Przemysław Kotyla; Olga Gumkowska-Sroka; Bartosz Wnuk; Kacper Kotyla
Journal:  Pharmaceuticals (Basel)       Date:  2022-07-28
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.